Vascular calcification and cardiac function according to residual renal function in patients on hemodialysis with urination

Dong Ho Shin¹, Young-Ki Lee²*, Jieun Oh¹*, Jong-Woo Yoon³*, So Yon Rhee¹, Eun-Jung Kim¹, Jiwon Ryu³, Ajin Cho², Hee Jung Jeon¹, Myung-Jin Choi³, Jung-Woo Noh²

¹ Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea, ² Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea, ³ Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Gangwon-do, Korea

* These authors contributed equally to this work.
* km2071@naver.com (YKL); jieunmd@gmail.com (JO); yoonjw@hallym.or.kr (JWY)

Abstract

Background

Vascular calcification is common and may affect cardiac function in patients with end-stage renal disease (ESRD). However, little is known about the effect of residual renal function on vascular calcification and cardiac function in patients on hemodialysis.

Methods

This study was conducted between January 2014 and January 2017. One hundred sixty patients with residual renal function on maintenance hemodialysis for 3 months were recruited. We used residual renal urea clearance (KRU) to measure residual renal function. First, abdominal aortic calcification score (AACS) and brachial-ankle pulse wave velocity (baPWV) were measured in patients on hemodialysis. Second, we performed echocardiography and investigated new cardiovascular events after study enrollment.

Results

The median KRU was 0.9 (0.3–2.5) mL/min/1.73m². AACS (4.0 [1.0–10.0] vs. 3.0 [0.0–8.0], p = 0.05) and baPWV (1836.1 ± 250.4 vs. 1676.8 ± 311.0 cm/s, p = 0.01) were significantly higher in patients with a KRU < 0.9 mL/min/1.73m² than a KRU ≥ 0.9 mL/min/1.73m². Log-KRU significantly negatively correlated with log-AACS (β = -0.29, p = 0.002) and baPWV (β = -0.19, P = 0.05) after factor adjustment. The proportion of left ventricular diastolic dysfunction was significantly higher in patients with a KRU < 0.9 mL/min/1.73m² than with a KRU ≥ 0.9 mL/min/1.73m² (67.9% vs. 49.1%, p = 0.05). Patients with a KRU < 0.9 mL/min/1.73m² showed a higher tendency of cumulative cardiovascular events compared to those with a KRU ≥ 0.9 mL/min/1.73m² (P = 0.08).
Conclusions
Residual renal function was significantly associated with vascular calcification and left ventricular diastolic dysfunction in patients on hemodialysis.

Introduction
Cardiovascular disease is the leading cause of death in patients with end-stage renal disease (ESRD) [1,2]. However, traditional cardiovascular risk factors do not fully explain the elevated mortality rates of cardiovascular disease seen in patients with ESRD. Vascular calcification is a common pathologic finding among patients with ESRD that has a variety of forms, including the deposition of calcium in the intimal and/or medial vessel layer [3,4]. Previous studies suggested that this change in vessels might be induced by multiple factors such as using calcium-based phosphate binder, calcium-phosphorous products, oxidative stress, inflammation, and erythropoietin stimulating agent (ESA) resistance [5,6]. Eventually, vascular calcification greatly contributes to the exceedingly high cardiovascular disease mortality in this population [7]. Vascular calcification is related to vascular stiffness. Therefore, cardiovascular assessments including vascular calcification and stiffness are important to predict cardiovascular mortality in patients with ESRD. Of note, ambulatory blood pressure monitoring (ABPM), pulse wave velocity (PWV), and plain radiography are known to predict the severity of vascular calcification [8–10]. Especially, increased vascular stiffness, as measured by PWV, is associated with increased cardiovascular and all-cause mortality in patients with ESRD [11].

Residual renal function may contribute to better anemia and volume control, lower inflammation degrees, malnutrition, and calcium-phosphorous products, and greater solute clearance [12–15]. Thus, these beneficial effects explained the lower overall and cardiovascular mortality in dialysis patients with residual renal function. In fact, the importance of residual renal function in cardiovascular disease has been confirmed in many studies related to peritoneal dialysis [12–16]. There are several observational studies about the importance of residual renal function in patients on hemodialysis [17–20]. However, in most studies of hemodialysis, residual renal function was defined according to urine output and end points were analyzed using hard outcomes such as cardiovascular mortality. Therefore, identification of factors related with cardiovascular events was needed to evaluate them based on residual renal function expressed as glomerular filtration rate (GFR). Although several studies demonstrated the role of residual renal function expressed as GFR in phosphate management, anemia control, and solute clearance in patients on hemodialysis [21, 22], little is known about vascular calcification and cardiac function according to residual renal function expressed as GFR in patients on hemodialysis. Here we hypothesis that residual renal function was associated with vascular calcification and cardiac function and it affected cardiovascular events. Therefore, we investigated the correlation between residual renal function expressed as GFR and vascular calcification in patients on hemodialysis and conducted echocardiography in those patients. Furthermore, new cardiovascular events were evaluated after study enrollment.

Materials and methods
Ethics statement
This study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Kangdong Sacred Heart Hospital, Kangnam Sacred Heart
Patients

This study was conducted at three dialysis clinics in Kangdong Sacred Heart Hospital, Kangnam Sacred Heart Hospital, and Chuncheon Sacred Heart Hospital between January 2014 and January 2017. One hundred and twenty, 111, and 108 patients were on Hemodialysis therapy in Kangdong Sacred Heart Hospital, Kangnam Sacred Heart Hospital, and Chuncheon Sacred Heart Hospital between January 2014 and February 2015, respectively. The inclusion criteria were as follow: patients with age $\geq 18$ years with urination, patients with hemodialysis duration of at least three months, and patients with hemodialysis prescription of three times a week for four hours each time. Exclusion criteria were as follow: patients conducting hemodialysis due to chronic rejection after kidney transplantation, patients planning to transfer other hemodialysis center, and patients failing to undergo measurement of PWV or echocardiography. At three hospitals, 131 patients were considered eligible for study inclusion in that period. Of the 131 enrolled patients, four patients conducted hemodialysis due to chronic rejection after kidney transplantation, 12 patients planned to transfer other hemodialysis center, and nine patients did not undergo the measurement of PWV ($n = 4$) or echocardiography ($n = 5$). Thus, 106 patients were included in this study.

Data collection

Baseline characteristics, including demographic, clinical, and biochemical data were obtained from medical records at the time of PWV measurement. Mean interdialytic weight gain was calculated as the average of 10 values after the time of PWV measurement. Echocardiography, abdominal plain radiography, urine collection of interdialytic period, and ABPM were conducted within one week at the time of PWV measurement.

Definition

Cardiovascular disease was defined as a history of coronary artery disease, arrhythmia, cerebrovascular disease, or peripheral vascular disease; Coronary artery disease was defined as a history of angioplasty, coronary artery bypass grafting, myocardial infarction, or angina; Cerebrovascular disease was defined as a previous history of transient ischemic attack, stroke, or carotid endarterectomy; and Peripheral artery disease was defined as a history of claudication, ischemic limb loss and/or ulceration, or a peripheral revascularization procedure. Cardiovascular events were designated as events requiring hospitalization or emergency room visit because of cardiovascular disease. ESA resistance to erythropoietin stimulating agents was defined as failure to achieve target hemoglobin levels (11–12 g/dL) with an epoetin dose $< 300$ IU/kg/week or a darbopoietin-$\alpha$ dose of 1.5 $\mu$g/week [23]. Non-dipper was defined as blood pressure decline of $< 10\%$ at night compared to that during the day [24].

Measurement of residual renal function

Blood was sampled at the end of the first dialysis session of the week (blood urea 1) and immediately before the next session (blood urea 2). Between these blood samples, urine was collected throughout the interdialytic period. Residual renal urea clearance (KRU) was calculated using
the following formula [25]:

\[
\text{Urea clearance (mL/min)} = \frac{2 \times (\text{urine urea concentration} \times \text{urine volume})}{\text{urine collection duration} \times (\text{blood urea 1} + \text{blood urea 2})}
\]

**Abdominal aortic calcification score**

A lateral lumbar X-ray of the abdominal aorta was used to determine abdominal aortic calcification score (AACS) as described by Kauppila et al [9]. A lateral radiograph of the abdomen was performed in a standing position and the aorta was identified as the tubular structure coursing in front of the anterior surface of the spine. We used a semi-quantitative scoring system; only the abdominal aorta segments in front of the first to fourth lumbar vertebrae were considered. Points were assigned on a 0–3 scale to areas of calcification identified along the anterior or posterior surface of the aorta (0, absent; 1, small; 2, moderate; 3, large) according to the length of each calcified plaque with respect to the craniocaudal length of the closest vertebra. All radiographs were read by two investigators and consensus was reached on the interpretation of all films.

**Assessment of pulse wave velocity**

Brachial-ankle PWV (baPWV) was measured using a Vascular profiler 1000 (VP-1000; Colin Co. Ltd., Komaki, Japan). Brachial and post-tibia arterial pressure waveforms were stored for 10 seconds by using extremity cuffs connected to a plethysmographic sensor and an oscillometric pressure sensor wrapped around the arm and ankle. The baPWV was automatically calculated from the distance between two arterial recording sites divided by transit time. The upper limits of baPWV were 1394/1264 cm/s, 1435/1361 cm/s, 1552/1433 cm/s, 1597/1609 cm/s and 1798/1915 cm/s for healthy male/female at 10 years interval (age range 20–70) [26].

**Measurement of ambulatory blood pressure monitoring**

Twenty-four hour blood pressure monitoring was performed using Model P6 pressurometer device (Del Mar ReynoldsMedical Ltd., Hertford, United Kingdom) and the results were assessed using its computer software. An ocillometric cuff was attached to the upper arm without vascular access for hemodialysis. Patients were requested to have a rest for 10 minutes before the measurements. The Operations were performed according to the strict instruction. The measurements were performed at 15 minutes intervals during the day (06:00–24:00) and 30 minutes intervals at night (0:00–6:00).

**Echocardiographic measurements**

Comprehensive echocardiographic measurements were performed using an ultrasound machine (Vivid 7; GE Vingmed Ultrasound AS, Horten, Norway) with a 2.5 MHz probe, based on the imaging protocol in the American Society of Echocardiography guideline [27]. Left ventricular ejection fraction (LVEF) was estimated using the modified biplane Simpson’s method in apical two and four-chamber views. LV mass was determined using the method described by Devereus et al. and LV mass index (LVMI) was calculated by dividing the LV mass by the body surface area. Mitral inflow was assessed with Doppler echocardiography from the apical four-chamber view. The mitral inflow profiles were used to measure the peak mitral inflow velocities at the early (E), late (A) diastole, and its deceleration time (DT). Doppler tissue imaging of the mitral annulus was also obtained. From the apical four-chamber view, the early (E’)...
and late (A') diastolic peak velocities were evaluated. Moderate to severe diastolic dysfunction was defined as E/E' > 15 [28].

Statistical analyses
Statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to test the normality of continuous variables. The normally distributed variables were expressed as mean ± SD and compared with the student’s t-test for two groups. The non-normally distributed variables were expressed as median and interquartile range and compared with Mann-Whitney U test for two groups. The categorical variables were expressed by frequencies and percentages and compared with either the chi-square test or Fisher’s exact test. The factors associated with AACS and baPWV were ascertained by multivariate regression analyses, which included age, the underlying cause of ESRD, duration on dialysis, mean interdialytic weight gain, and KRU. AACS, Ca × P, CRP, KRU, and parathyroid hormone, being non-normally distributed, were log-transformed before inclusion into the model. The cumulative incidence of cardiovascular events was calculated using the Kaplan-Meier product estimation method.

Results
Baseline characteristics according to residual renal urea clearance
The baseline characteristics of all patients and those when the patients were subsequently divided according to median KRU (0.9 mL/min/1.73m²) are shown in Table 1. The mean age was 59.1 ± 11.0 years and 55 (51.9%) were male. The median dialysis duration was 28.4 (interquartile range, 10.9–49.2) months. The underlying cause of ESRD was diabetes in 60 patients (56.6%). Compared to patients with a KRU ≥ 0.9 ml/min/1.73m², those with a KRU < 0.9 ml/min/1.73m² had a longer hemodialysis duration, larger mean interdialytic weight gain, and greater likelihood of taking calcium-based phosphate binders and diuretics, and resistance to ESA. In addition, the C-reactive protein (CRP) and β2-microglobulin levels were higher in patients with a KRU < 0.9 mL/min/1.73m². Furthermore, AACS (4.0 [1.0–10.0] vs. 3.0 [0.0–8.0], P = 0.05) and baPWV (1836.1 ± 250.4 vs. 1676.8 ± 311.0 cm/s, p = 0.01) were significantly higher in patients with a KRU < 0.9 mL/min/1.73m² than patients with a KRU ≥ 0.9 ml/min/1.73m².

Determining factors for abdominal aortic calcification score and Brachial-ankle PWV
On univariate analyses, log-AACS was significantly positively associated with age (β = 0.38, p < 0.001), diabetes (β = 0.25, p = 0.01), and mean interdialytic weight gain (β = 0.27, p = 0.01). However, it was significantly negatively associated with log-KRU (β = -0.32, p = 0.001). Log-KRU remained a significant negative correlation with log-AACS after adjusting age, the underlying cause of ESRD, duration on dialysis, and mean interdialytic weight gain (β = -0.29, p = 0.002) (Table 2). In addition, on multivariate analysis, log-KRU remained also a significant negative correlation with baPWV (β = -0.19, p = 0.05) (Table 3).

Echocardiographic parameters according to residual renal urea clearance
Table 4 presents the echocardiographic parameters of the two groups. The proportion of moderate to severe left ventricular diastolic dysfunction (67.9% vs. 49.1%, p = 0.05) were significantly higher in patients with a KRU < 0.9 mL/min/1.73m² than in those with a KRU ≥ 0.9
Table 1. Demographics, clinical characteristics, and biochemical variables in hemodialysis patients according to KRU.

| Variables                          | Total (n = 106) | KRU < 0.9 mL/min/1.73m² (n = 53) | KRU ≥ 0.9mL/min/1.73m² (n = 53) | p-value |
|-----------------------------------|----------------|-----------------------------------|----------------------------------|---------|
| **Demographic data**              |                |                                   |                                  |         |
| Age (years)                       | 59.1 ± 11.0    | 58.2 ± 9.1                        | 60 ± 12.7                        | 0.39    |
| Male, n (%)                       | 55 (51.9)      | 26 (49.1)                         | 29 (54.7)                        | 0.70    |
| **Clinical data**                 |                |                                   |                                  |         |
| Duration of hemodialysis (months) | 28.4 (10.9–49.2)| 37.4 (19.5–56.6)                 | 13.6 (7.0–42.9)                  | <0.001  |
| Initial end-stage renal disease   |                |                                   |                                  | 0.70    |
| Diabetes, n (%)                   | 60 (56.6)      | 31 (58.5)                         | 29 (54.7)                        |         |
| Non-diabetes, n (%)               | 46 (43.4)      | 22 (41.5)                         | 24 (45.3)                        |         |
| **Previous cardiovascular disease** |              |                                   |                                  |         |
| Coronary artery disease, n (%)    | 43 (40.6)      | 23 (43.4)                         | 20 (37.0)                        | 0.99    |
| Peripheral artery disease, n (%)  | 17 (16.0)      | 7 (13.2)                          | 10 (18.9)                        | 0.43    |
| Cerebrovascular disease, n (%)    | 2 (1.9)        | 1 (1.9)                           | 1 (1.9)                          | 0.99    |
| Mean interdialytic weight gain (kg) | 1.5 ± 1.2      | 1.9 ± 1.3                         | 1.1 ± 1.0                        | <0.001  |
| Residual renal urine (cc)         | 600 (200–1000) | 250 (120–400)                     | 1000 (800–1575)                  | <0.001  |
| **Medication use**                |                |                                   |                                  |         |
| Vitamin D analogs, n (%)          | 55 (51.9)      | 27 (50.9)                         | 28 (52.8)                        | 0.76    |
| Calcium-based phosphate binder, n (%) | 45 (42.5)    | 30 (56.6)                         | 15 (28.3)                        | 0.01    |
| Non calcium-based phosphate binder, n (%) | 12 (11.3)   | 8 (15.1)                          | 4 (8.0)                          | 0.42    |
| Diuretics, n (%)                  | 74 (69.8)      | 32 (60.4)                         | 42 (79.2)                        | 0.03    |
| ACEi or ARB, n (%)                | 74 (69.8)      | 36 (67.9)                         | 38 (71.7)                        | 0.67    |
| ESA, n (%)                        | 90 (84.9)      | 46 (86.8)                         | 44 (83.0)                        | 0.85    |
| Resistance, n (%)                 | 11 (10.4)      | 8 (15.1)                          | 2 (3.8)                          | 0.05    |
| **Laboratory data**               |                |                                   |                                  |         |
| Hemoglobin (g/dL)                 | 10.1 ± 1.2     | 10.1 ± 1.1                        | 10.2 ± 1.3                       | 0.85    |
| Albumin (g/dL)                    | 3.8 ± 0.5      | 3.8 ± 0.4                         | 3.7 ± 0.5                        | 0.86    |
| Calcium (mg/dL)                   | 8.7 (8.1–9.1)  | 8.7 (8.1–9.1)                     | 8.6 (8.2–8.9)                    | 0.92    |
| Phosphate (mg/dL)                 | 4.5 ± 1.2      | 4.6 ± 1.4                         | 4.4 ± 1.1                       | 0.51    |
| Ca × P (mg²/dL²)                  | 40.0 (31.9–44.4)| 40.5 (34.2–45.1)                  | 38.3 (30.8–43.8)                 | 0.28    |
| Cholesterol (mg/dL)               | 138 (107.5–163.5)| 138 (107.0–160.0)                | 140.0 (110.5–164.5)              | 0.38    |
| Triglyceride (mg/dL)              | 93.5 (65.0–147.3)| 88.0 (57.0–129.0)                | 104.0 (78.5–158.0)               | 0.07    |
| High-density lipoprotein (mg/dL)  | 41.0 (32.0–51.0)| 41.0 (31.0–53.0)                  | 41.0 (33.5–49.5)                 | 0.83    |
| Low-density lipoprotein (mg/dL)   | 78.0 (58.0–95.0)| 72.0 (53.0–89.0)                  | 86.0 (82.0–103.0)                | 0.02    |
| CRP (mg/L)                        | 0.6 (0.3–1.6)  | 0.9 (0.4–3.0)                     | 0.5 (0.3–1.1)                    | 0.03    |
| Parathyroid hormone (pg/dL)       | 204.0 (105.7–398.6)| 243.8 (102.4–415.2)             | 196.6 (118.8–346.0)              | 0.65    |
| ß2-microglobulin (mg/L)           | 19.9 ± 6.8     | 22.4 ± 6.7                        | 17.3 ± 5.8                       | 0.01    |
| KRU (mL/min/1.73 m²)              | 0.9 (0.3–2.5)  | 0.3 (0.2–0.6)                     | 2.5 (1.5–3.0)                    | <0.001  |
| Single-pool Kt/V                  | 1.6 ± 0.3      | 1.6 ± 0.4                         | 1.5 ± 0.3                        | 0.59    |
| AACS                              | 3.0 (1.0–8.0)  | 4.0 (1.0–10.0)                    | 3.0 (0.0–8.0)                    | 0.05    |
| ABPM                              |                |                                   |                                  |         |
| Daytime mean blood pressure       | 106.8 ± 13.5   | 108.9 ± 14.4                      | 104.5 ± 12.4                     | 0.09    |
| Nighttime blood pressure          | 101.5 ± 14.9   | 102.6 ± 15.4                      | 100.4 ± 14.3                     | 0.47    |
| Non-dipper, n (%)                 | 79 (74.5)      | 41 (80.4)                         | 38 (79.2)                        | 0.99    |
| baPWV (cm/s)                      | 1756.5 ± 292.2 | 1836.1 ± 250.4                    | 1676.8 ± 311.0                   | 0.01    |

Note: values are expressed as median ± SD or median (interquartile range) or number (percentage).

Abbreviations: AACS, abdominal aortic calcification score; ABPM, ambulatory blood pressure monitoring; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; baPWV, brachial-ankle pulse wave velocity; Ca × P, calcium × phosphate; CRP, C-reactive protein; ESA, erythropoiesistimulating agent; KRU, residual renal urea clearance.

https://doi.org/10.1371/journal.pone.0185296.t001
In addition, on multivariate regression analysis, log-KRU remained also a significant negative correlation with the E/E' ratio of echocardiographic parameters (S1 Table). Of note, AACS (5.0 [1.0–9.0] vs. 2.0 [0.0–6.0], p = 0.01) and baPWV (1825.6 ± 306.9 vs. 1659.0 ± 241.2 cm/s, p = 0.003) were significantly higher in patients with moderate to severe left ventricular diastolic dysfunction than patients without that.

Cardiovascular events according to residual renal urea clearance

During a mean follow-up of 21.4 ± 7.1 months, 14 patients on HD (13.0%) experienced cardiovascular events. Of these patients, 10, three, and one experienced coronary artery disease, arrhythmia, and cerebrovascular disease, respectively. Cardiovascular events occurred in patients on HD with a KRU ≥ 0.9 mL/min/1.73m² (four patients; 7.5%) and in patients on

Table 2. Determining factors for abdominal calcification score in hemodialysis patients with residual renal function.

| Univariate model | Multivariate model |
|------------------|--------------------|
|                  | Beta   | standard error | p-value | Beta   | standard error | p-value |
| Age (y)          | 0.38   | 0.01            | <0.001  | 0.39   | 0.01            | <0.001  |
| Male (vs. female)| 0.16   | 0.19            | 0.09    |        |                |         |
| Initial end-stage renal disease (Diabetes vs. non-diabetes) | 0.25 | 0.19 | 0.01 | 0.22 | 0.17 | 0.01 |
| Log-duration of hemodialysis (months) | -0.05 | 0.41 | 0.64 | 0.01 | 0.35 | 0.99 |
| Mean interdialytic weight gain (kg) | 0.27 | 0.08 | 0.01 | 0.17 | 0.08 | 0.64 |
| Log-KRU (mL/min/1.73m²) | -0.32 | 0.17 | 0.001 | -0.29 | 0.16 | 0.002 |
| Use of vitamin D analogs | -0.12 | 0.20 | 0.25 |        |                |         |
| Use of calcium-based phosphate binders | 0.15 | 0.19 | 0.14 |        |                |         |
| Log-(Ca × P) (mg²/dL²) | 0.02 | 0.49 | 0.81 |        |                |         |
| Log-CRP (mg/L) | 0.07 | 0.18 | 0.53 |        |                |         |
| Log-Parathyroid hormone (pg/dL) | -0.11 | 0.23 | 0.30 |        |                |         |
| β2-Microglobulin (mg/L) | 0.08 | 0.01 | 0.46 |        |                |         |

Abbreviations: Ca × P: calcium × phosphate; CRP, C-reactive protein; KRU, residual renal urea clearance.

https://doi.org/10.1371/journal.pone.0185296.t002

Table 3. Determining factors for brachial-ankle pulse wave velocity in hemodialysis patients with residual renal function.

| Univariate model | Multivariate model |
|------------------|--------------------|
|                  | Beta   | standard error | p-value | Beta   | standard error | p-value |
| Age (y)          | -0.01  | 2.61            | 0.98    | 0.01   | 2.56            | 0.94    |
| Male (vs. female)| 0.05   | 56.99           | 0.61    |        |                |         |
| Initial end-stage renal disease (Diabetes vs. non-diabetes) | 0.39 | 53.00 | <0.001 | 0.38 | 54.14 | <0.001 |
| Log-duration of hemodialysis (months) | -0.09 | 120.78 | 0.38 | -0.10 | 113.61 | 0.28 |
| Mean interdialytic weight gain (kg) | 0.20 | 24.80 | 0.05 | 0.13 | 24.44 | 0.18 |
| Log-KRU (mL/min/1.73m²) | -0.25 | 50.21 | 0.01 | -0.19 | 52.24 | 0.05 |
| Use of vitamin D analogs | 0.11 | 58.86 | 0.27 |        |                |         |
| Use of calcium-based phosphate binders | 0.16 | 58.12 | 0.10 |        |                |         |
| Log-(Ca × P) (mg²/dL²) | -0.16 | 150.38 | 0.12 |        |                |         |
| Log-CRP (mg/L) | -0.16 | 54.92 | 0.11 |        |                |         |
| Log-Parathyroid hormone (pg/dL) | 0.02 | 71.36 | 0.82 |        |                |         |
| β2-Microglobulin (mg/L) | 0.08 | 4.38 | 0.42 |        |                |         |

Abbreviations: Ca × P: calcium × phosphate; CRP, C-reactive protein; KRU, residual renal urea clearance.

https://doi.org/10.1371/journal.pone.0185296.t003
Although the Kaplan-Meier analysis revealed no significant intergroup difference, there is a trend that cumulative cardiovascular events were higher in patients with a KRU < 0.9 mL/min/1.73 m² than with a KRU ≥ 0.9 mL/min/1.73 m² (p = 0.08) (Fig 1).

### Discussion

This study showed that an increased AACS and baPWV were independently associated with deterioration of residual renal function. In addition, the proportion of left ventricular diastolic dysfunction was higher in patients with low residual renal function than in those with high...
residual renal function. Finally, Patients with low residual renal function showed a higher tendency of cumulative cardiovascular events compared to those with high residual renal function.

In our study, the proportion of patients taking calcium-based phosphate binders and with ESA resistance and β2-microglobulin and CRP levels were higher in patients with a KRU $< 0.9$ mL/min/1.73m$^2$ than in those with a KRU $\geq 0.9$ mL/min/1.73m$^2$, which was consistent with other studies [18,21,29,30]. Although there had been lack of a standardized definition of residual renal function, the presence of residual renal function in patients on hemodialysis was defined as $> 200$ mL of urine/24 hours in many studies [21, 31–33]. However, in our study, patients on hemodialysis with the presence of urine were included regardless of urine volume. This may explain why median residual renal function expressed as GFR in our study was lower than those reported in other studies [21,29].

KRU is practically and widely used to measure residual renal function in dialysis. In patients on hemodialysis, residual renal function may vary over the dialysis cycle; thus, urine collection is required during the interdialytic period, usually 44 hours or 2 days to accurately estimate residual renal function. However, this can be difficult and inconvenient for patients on hemodialysis. In addition, the common belief that renal function rapidly declines after the initiation of hemodialysis may underestimate the importance of residual renal function in patients on hemodialysis. For these reasons, many studies of residual renal function have been performed in peritoneal dialysis patients. However, this study involved urine collection during the interdialytic period to estimate residual renal function in patients on hemodialysis.

Vascular calcification is common in patients with ESRD. The severity of vascular calcification has been assessed using several methods [9,34]. Although cardiac computed tomography is a very accurate and reliable method for assessing cardiovascular calcification extent [34], it is expensive and involves radiation exposure. Therefore, the KDIGO consensus suggested the use of routine lateral lumbar radiography to measure AACS in clinical practice [35]. In addition, PWV and non-dipper pattern of ABPM is related with vascular stiffness. Although carotid-femoral PWV (cfPWV) is the current gold standard method for assessing central arterial stiffness [36], as of convenience and feasibility, a simpler method of measuring PWV called baPWV is widely used in clinical practice.

Recent studies suggested that the vascular calcification of CKD patients is not simple precipitate calcium-phosphorous products but is related with multiple factors in the pathological process [37]. Generally, β2-microglobulin levels increase when RRF deteriorates in HD patients. Although it is still unknown whether β2-microglobulin is only a uremic toxin marker or also an active player in vascular damage, preclinical and clinical studies have shown that it plays an active role in vascular calcification [38]. Therefore, retained β2-microglobulin seems to further contribute to the vascular calcification process in the uremic milieu. In addition, oxidative stress and inflammation are also considered to play a key role [5]. Interestingly, Won et al showed that ESA resistance was associated with vascular calcification, which could be explained based on oxidative stress and inflammation [5]. Meanwhile, Stompor et al. described that higher residual renal function in dialysis patients was responsible for better clearance of proinflammatory cytokines [39]. Vascular calcification caused by these multiple factors is related to vascular stiffness. However, volume overload also increases vascular stiffness by vascular distension (Laplace’ law) [40]. Therefore, high interdialytic weight gain induced by deterioration of residual renal function is associated with increased vascular stiffness in patients on hemodialysis. Taken together, following the decrease in residual renal function of dialysis patients, the accumulation of proinflammatory cytokines and β2-microglobulin, and high interdialytic weight gain may induce the increase of vascular calcification and stiffness. Likewise, in the present study, we clearly showed that although AACS was not associated with the
calcium-phosphorous products, it was significantly negatively correlated with KRU. In addition, baPWV was also significantly negatively correlated with KRU. However, because the proportion of non-dipper pattern was high in this study, there was no difference in non-dipper pattern according to KRU.

Vascular calcification and stiffness reduce aortic and arterial elastance, which impairs cardiovascular hemodynamics in patients with ESRD. In particular, aortic calcification cause left ventricular diastolic dysfunction by eroding compliance and elasticity [41]. In line with this finding, in this study, patients with moderate to severe left ventricular diastolic dysfunction showed higher AACS and baPWV than those without moderate to severe left ventricular diastolic dysfunction. In addition, the E/E’ ratio of echocardiographic parameters were independently associated with deterioration of residual renal function in this study. Of note, left ventricular diastolic dysfunction is known as an ongoing cardiovascular challenge and may be an independent predictor of cardiovascular events in dialysis patients [41].

In summary, the association of residual renal function with cardiovascular disease can be explained by more accumulated cytokines and uremic toxin and greater interdialytic weight gain given the likely more rapid loss of residual renal function. Although there was no significant difference in cardiovascular events in all patients with low residual renal function compared to those with high residual renal function, considering the short-term follow-up period of this study, a long observation period is required.

Our study had several limitations. First, the cause and effect relationship of residual renal function, vascular calcification, and left ventricular diastolic dysfunction cannot be determined using the cross-sectional study design. Second, the number of patients was small and follow-up period of this study was short to confirm whether residual renal function was an independent factor affecting cardiovascular events. Third, there was the possibility of inaccurate urine collection during the interdialytic period for measuring KRU. In addition, KRU measures only small molecule solute clearance, whereas residual renal function also contributes to convective clearance of mid-sized molecules. Therefore, KRU may not represent residual renal function. Fourth, because baPWV may be influenced by peripheral stiffness, cfPWV is a golden-standard method to measure aortic stiffness rather than peripheral baPWV.

In conclusion, although patients with high residual renal function had so much shorter hemodialysis duration before study enrollment in this study, it showed that increased AACS and baPWV were independently associated with deterioration of residual renal function after factor adjustment including hemodialysis duration. In addition, we founded that residual renal function was also independent factor for left ventricular diastolic dysfunction predicting cardiovascular events. However, these results also make it difficult to confirm the causal relationship between cardiovascular events and residual renal function. To confirm it, the analysis of time-to-event must be needed following the data is accumulated.

Supporting information

S1 Table. Determining factors for the E/E’ ratio among echocardiographic parameters in hemodialysis patients with residual renal function.

(DOC)

S1 File. Participant-level data.

(XLS)

Acknowledgments

We thank dialysis nurses for their dedication to care of hemodialysis patients and for their help in the collection of data from these patients.
Author Contributions

Conceptualization: Young-Ki Lee, Jieun Oh, Jong-Woo Yoon.

Data curation: So Yon Rhee, Jiwon Ryu, Ajin Cho, Hee Jung Jeon, Myung-Jin Choi, Jung-Woo Noh.

Formal analysis: Dong Ho Shin.

Investigation: Young-Ki Lee, Jieun Oh, Jong-Woo Yoon.

Methodology: Dong Ho Shin.

Project administration: Dong Ho Shin.

Resources: So Yon Rhee, Eun-Jung Kim, Jiwon Ryu, Ajin Cho.

Software: Dong Ho Shin.

Supervision: Young-Ki Lee, Jieun Oh, Jong-Woo Yoon.

Validation: Jieun Oh.

Visualization: Dong Ho Shin.

Writing – original draft: Dong Ho Shin.

Writing – review & editing: Dong Ho Shin, Young-Ki Lee.

References

1. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003; 16: 101–105. PMID: 12641872

2. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16: 489–495. https://doi.org/10.1681/ASN.2004030203 PMID: 15590763

3. Hruska KA, Mathew S, Lund RJ, Memon I, Saab G. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2008; 29: 156–165. https://doi.org/10.1016/j.semnephrol.2009.01.008 PMID: 19371806

4. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004; 43: 572–579. PMID: 14981617

5. Won HS, Choi SJ, Yun YS, Shin OR, Ko YH, Kim YS, et al. Resistance to erythropoiesis-stimulating agents is associated with arterial microcalcification in early hemodialysis patients. Biomed Res Int. 2014; 2014: 731296. https://doi.org/10.1155/2014/731296 PMID: 24772434

6. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep. 2012; 14: 228–237. https://doi.org/10.1007/s11906-012-0265-8 PMID: 22476974

7. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet. 1996; 348: 1673–1674. https://doi.org/10.1016/S0140-6736(05)65816-3 PMID: 8973424

8. Stompor T, Rajzer M, Pasowicz M, Krasniak A, Sulowicz W, Kawecka-Jaszcz K, et al. Coronary artery calcification, common carotid artery intima-media thickness and aortic pulse wave velocity in patients on peritoneal dialysis. Int J Artif Organs. 2006; 29: 736–744. PMID: 16969750

9. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997; 132: 249–250. PMID: 9249271

10. Velasquez MT, Beddu S, Nobakht E, Rahman M, Raj DS. Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time? Kidney Int Rep. 2016; 1: 94–104. https://doi.org/10.1016/j.ekir.2016.05.001 PMID: 28164170

11. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999; 99: 2434–2439. PMID: 10318666
12. Wang AY, Woo J, Wang M, Sea MM, Sanderson JE, Lui SF, et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant. 2005; 20: 396–403. https://doi.org/10.1093/ndt/gfh331 PMID: 15187196

13. Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int. 2002; 62: 639–647. https://doi.org/10.1046/j.1523-1755.2002.00747.x PMID: 12110029

14. Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis. 2004; 43: 712–720. PMID: 15042549

15. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003; 64: 2238–2243. https://doi.org/10.1046/j.1523-1755.2003.00310.x PMID: 14633148

16. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int. 2006; 69: 1726–1732. https://doi.org/10.1038/sj.ki.5000482 PMID: 16612329

17. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis. 2010; 56: 348–358. https://doi.org/10.1053/j.ajkd.2010.03.020 PMID: 20605303

18. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38: 85–90. https://doi.org/10.1053/ajkd.2001.25198 PMID: 11431186

19. Suda T, Hiroshige K, Ohta T, Watanabe Y, Iwamoto M, Kanegae K, et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant. 2000; 15: 396–401. PMID: 10692527

20. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis. 2007; 49: 426–431. https://doi.org/10.1053/j.ajkd.2006.12.012 PMID: 17336704

21. Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nube MJ, et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011; 6: 281–289. https://doi.org/10.2215/CJN.04480510 PMID: 21030579

22. Marquez IO, Tambra S, Luo FY, Li Y, Plummer NS, Hostetter TH, et al. Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol. 2011; 6: 290–296. https://doi.org/10.2215/CJN.06100710 PMID: 21030575

23. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 Suppl 2: ii1–47.

24. Birkenhager AM, van den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. Neth J Med. 2007; 65: 127–131. PMID: 17452760

25. Daugirdas JT, Blake PG, Ings TS. Handbook of dialysis: Lippincott Williams & Wilkins; 2012.

26. Wang X, Xie J, Zhang LJ, Hu DY, Luo YL, Wang JW. Reference values of brachial-ankle pulse wave velocity for Northern Chinese. Chin Med J (Engl). 2009; 122: 2103–2106.

27. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 1997; 10: 246–270. PMID: 9109691

28. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28: 2539–2550. https://doi.org/10.1093/eurheartj/ehm037 PMID: 17428822

29. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fahrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41: 1212–1218. PMID: 12776273

30. Fry AC, Singh DK, Chandra SM, Farrington K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif. 2007; 25: 295–302. https://doi.org/10.1159/000104870 PMID: 17622712
31. Zhang M, Wang M, Li H, Yu P, Yuan L, Hao C, et al. Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol. 2014; 40: 140–150. https://doi.org/10.1159/000365819 PMID: 25171342

32. Rroji M, Seferi S, Cafka M, Petrela E, Barbullushi M, et al. Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients? Int Urol Nephrol. 2014; 46: 175–182. https://doi.org/10.1007/s11255-013-0438-7 PMID: 23591721

33. Wong J, Sridharan S, Berdeprado J, Vilar E, Viljoen A, Wellsted D, et al. Predicting residual kidney function in hemodialysis patients using serum beta-trace protein and beta2-microglobulin. Kidney Int. 2016; 89: 1090–1098. https://doi.org/10.1016/j.kint.2015.12.042 PMID: 26924065

34. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832. PMID: 2407762

35. Honkanen E, Kauppila L, Wikstrom B, Rensma PL, Krzesinski JM, Aasarod K, et al. Abdominal aortic calcification in dialysis patients: results of the CORD study. Nephrol Dial Transplant. 2008; 23: 4009–4015. https://doi.org/10.1093/ndt/gfn403 PMID: 18676346

36. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 1236–1241. PMID: 11358934

37. Neven E, De Schutter TM, Behets GJ, Gupta A, D’Haese PC. Iron and vascular calcification. Is there a link? Nephrol Dial Transplant. 2011; 26: 1137–1145. https://doi.org/10.1093/ndt/gfq858 PMID: 21325349

38. Liabeuf S, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, et al. Plasma beta-2-microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int. 2012; 82: 1297–1303. https://doi.org/10.1038/ki.2012.301 PMID: 22895515

39. Stompor T, Zdzienicka A, Motyka M, Dembinska-Kiec A, Davies SJ, Sulowicz W. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int. 2002; 22: 670–676. PMID: 12556068

40. Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, et al. Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994; 45: 1397–1400. PMID: 8072251

41. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008; 117: 2938–2948. https://doi.org/10.1161/CIRCULATIONAHA.107.743161 PMID: 18519861